# EDGAR Filing Document

**Accession Number:** 0001741021
**File Stem:** 0001493152-23-003486
**Filing Date:** 2023-2
**Character Count:** 8129
**Document Hash:** 9f637d4a593848590aa8c0f7195721a6
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-23-003486.hdr.sgml**: 20230203

**ACCESSION NUMBER**: 0001493152-23-003486

**CONFORMED SUBMISSION TYPE**: SC 13G/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230203

**DATE AS OF CHANGE**: 20230203

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Gene Biotherapeutics, Inc.
- **CENTRAL INDEX KEY:** 0000772320
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 840635673
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 13G/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-51647
- **FILM NUMBER:** 23584230

**BUSINESS ADDRESS:**
- **STREET 1:** 11750 SORRENTO VALLEY ROAD
- **STREET 2:** SUITE 250
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121
- **BUSINESS PHONE:** (858) 436-1000

**MAIL ADDRESS:**
- **STREET 1:** 11750 SORRENTO VALLEY ROAD
- **STREET 2:** SUITE 250
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Taxus Cardium Pharmaceuticals Group Inc.
- **DATE OF NAME CHANGE:** 20140318

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Cardium Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20060118

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Cadium Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20060118
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Jemapete Christopher J
- **CENTRAL INDEX KEY:** 0001741021

**FILING VALUES:**
- **FORM TYPE:** SC 13G/A

**MAIL ADDRESS:**
- **STREET 1:** 6888 SOUTH IRVINGTON COURT
- **CITY:** AURORA
- **STATE:** CO
- **ZIP:** 80016

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

**SCHEDULE 13G/A**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**(Amendment No. 1)\***

**GENE BIOTHERAPEUTICS, INC.**

(Name of Issuer)

**Common Stock**

(Title of Class of Securities)

**86767104 1**

(CUSIP Number)

**December 31, 2022**

(Date of Event which Requires Filing of This Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b) <br> ☒ Rule 13d-1(c) <br> ☐ Rule 13d-1(d)

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 867671041 Page 2 of 5 Pages

---

| | |
|:---|:---|
| 1 | NAMES OF REPORTING PERSONS |
|  | **Christopher J. Jemapete** |
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP |
|  | (a) ☐ |
|  | (b) ☐ |
| 3 | SEC USE ONLY |
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION |
|  | **United States** |

---

---

| | | |
|:---|:---|:---|
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH |
|  | 5 | SOLE VOTING POWER |
|  |  | **4,000,000** |
|  | 6 | SHARED VOTING POWER<br> **0** |
|  | 7 | SOLE DISPOSITIVE POWER |
|  |  | **4,000,000** |
|  | 8 | SHARED DISPOSITIVE POWER<br> **0** |

---

---

| | |
|:---|:---|
| 9.0 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON |
|  | **4000000** |
| 10.0 | CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ☐ |
| 11.0 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) |
|  | **6.2% (1)** |
| 12.0 | TYPE OF REPORTING PERSON\* |
|  | **IN** |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) The
 percent of class is based on 64,931,888 shares of the issuer's common stock issued and outstanding as of March 15, 2022,
 as reported on the issuer's Annual Report on Form 10-K/A filed with the Securities and Exchange Commission (the "SEC")
 on April 14, 2022.

CUSIP No. 867671041 Schedule 13G/A Page 3 of 5 Pages

**Item 1. Security and Issuer.**

&nbsp;&nbsp;&nbsp;&nbsp;(a) Name
 of issuer: Gene Biotherapeutics, Inc.

(b) Address
 of issuer's principal executive offices: 11230 Sorrento Valley Road, Suite 220, San Diego, California 92121

**Item 2.** 

(a) Name
 of person filing: Christopher J. Jemapete

(b) Address
 or principal business office or, if none, residence: 6888 S. Irvington Court, Aurora, CO 80016

(c) Citizenship:
 U.S.

(d) Title
 of class of securities: Common stock

(e) CUSIP
 No.: 86767104 1

**Item 3. Source and Amount of Funds or Other Consideration.**

**If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:**

&nbsp;&nbsp;&nbsp;&nbsp;(a) ☐ Broker
 or dealer registered under section 15 of the Act (15 U.S.C. 78o).

(b) ☐ Bank
 as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

(c) ☐ Insurance
 company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

(d) ☐ Investment
 company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

(e) ☐ An
 investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

(f) ☐ An
 employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

(g) ☐ A
 parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

(h) ☐ A
 savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i) ☐ A
 church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company
 Act of 1940 (15 U.S.C. 80a-3);

(j) ☐ Group,
 in accordance with §240.13d-1(b)(1)(ii)(J).

**Item 4. Ownership.**

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

&nbsp;&nbsp;&nbsp;&nbsp;(a) Amount
 beneficially owned: 4,000,000 shares

(b) Percent
 of class: 6.2%.

(c) Number
 of shares as to which the person has:

CUSIP No. 867671041 Schedule 13G/A Page 4 of 5 Pages

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Sole
 power to vote or to direct the vote: 4,000,000

(ii) Shared
 power to vote or to direct the vote: 0

(iii) Sole
 power to dispose or to direct the disposition of: 4,000,000

(iv) Shared
 power to dispose or to direct the disposition of: 0

**Item 5. Ownership of Five Percent or Less of a Class.**

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

*Instruction*. Dissolution of a group requires a response to this item.

**Item 6. Ownership of More than Five Percent on Behalf of Another Person.**

**Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.**

**Item 8. Identification and Classification of Members of the Group.**

**Item 9. Notice of Dissolution of Group.**

**Item 10. Certification.**

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

CUSIP No. 867671041 Schedule 13G/A Page 5 of 5 Pages

**SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

---

| | |
|:---|:---|
|  | **CHRISTOPHER J. JEMAPETE** |
| Dated: February 3, 2023 | */s/ Christopher J. Jemapete* |

---